4-(tert-butoxycarbonylmethylamino)acetoxy-3,5-dimethylbenzaldehyde | 241479-85-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-(tert-butoxycarbonylmethylamino)acetoxy-3,5-dimethylbenzaldehyde
• 英文别名: (4-Formyl-2,6-dimethylphenyl) 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetate；(4-formyl-2,6-dimethylphenyl) 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetate
• CAS: 241479-85-6
• 化学式: C₁₇H₂₃NO₅
• 分子量: 321.373
• InChiKey: FCHIGNYDDXYZKZ-UHFFFAOYSA-N

物化性质

• 沸点：
  434.2±45.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(tert-butoxycarbonylmethylamino)acetoxy-3,5-dimethylbenzaldehyde 在 sodium tetrahydroborate 、 四溴化碳 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 4-(N-叔丁氧羰基-N-甲基氨基乙酰氧基)-3,5-二甲基溴苄
  参考文献：
  名称：

  Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals

  摘要：

  Water soluble N-benzyltriazolium or N-benzylimidazolium salt type prodrugs of several highly lipophilic triazole or imidazole antifungals have been synthesized. They were designed to undergo an enzymatic activation followed by a self-cleavage to release a parent drug. The prodrugs such as 16 had enough chemical stability and water solubility for parenteral use and were rapidly and quantitatively converted to the active substance in human plasma. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00557-7
• 作为产物：
  描述：

  3,5-二甲基-4-羟基苯甲醛 、 叔丁氧羰酰基肌氨酸 在 4-二甲氨基吡啶 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以92%的产率得到4-(tert-butoxycarbonylmethylamino)acetoxy-3,5-dimethylbenzaldehyde
  参考文献：
  名称：

  Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals

  摘要：

  Water soluble N-benzyltriazolium or N-benzylimidazolium salt type prodrugs of several highly lipophilic triazole or imidazole antifungals have been synthesized. They were designed to undergo an enzymatic activation followed by a self-cleavage to release a parent drug. The prodrugs such as 16 had enough chemical stability and water solubility for parenteral use and were rapidly and quantitatively converted to the active substance in human plasma. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00557-7

文献信息

• Azoles for treatment of fungal infections
  申请人：Basilea Pharmaceutica AG, a Swiss Company

  公开号：US06300353B1

  公开（公告）日：2001-10-09

  Azole derivatives of the formula I wherein R14, R15 are each independently hydrogen or fluorine, T is a group of the formula: wherein R9 is pyrrolidinyl or a group A—NH—B—, A is hydrogen or straight-chain or branched C1-C5 alkyl; B is straight-chain or branched C1-C4 alkylene, —CH2—CONH—CH2 or —CH2CH2CH2—CH(NH2); and X− is a pharmaceutically acceptable anion; and pharmaceutically acceptable salts of said compounds, and hydrates and solvates of the compounds of formula I and the salts thereof can be used in the production of medicaments for treating fungal infections and mycoses.

  式I的氮唑衍生物 其中 R14，R15分别独立地是氢或氟， T是下式的基团： 其中 R9是吡咯烷基或A—NH—B—基团， A是氢或直链或支链的C1-C5烷基； B是直链或支链的C1-C4亚烷基，—CH2—CONH—CH2或—CH2CH2CH2—CH(NH2)；和 X−是药学上可接受的阴离子； 所述化合物的药学上可接受的盐，以及式I化合物及其盐的水合物和溶剂化合物可用于生产用于治疗真菌感染和霉菌病的药物。
• [EN] 3-[4-(4-CYANOPHENYL)THIAZOL-2-Y)]-1-(1H-1,2,4-TRIAZOL-1-YL)-BUTAN-2-OL DERIVATIVES HAVING ANTIFUNGAL ACTIVITY<br/>[FR] DERIVES 3-[4-(4-CYANOPHENYL)THIAZOL-2-Y)]-1-(1H-1,2,4-TRIAZOL-1-YL)-BUTAN-2-OL POSSEDANT UNE ACTIVITE ANTIFONGIQUE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：WO1999045008A1

  公开（公告）日：1999-09-10

  (EN) Azole derivatives of formula (I) wherein R14, R15 are each independently hydrogen or fluorine, T is a group of formula (T1) or (T2), wherein R9 is pyrrolidinyl or a group A-NH-B-, A is hydrogen or straight-chain or branched C1-C5 alkyl; B is straight-chain or branched C1-C4 alkylene, -CH2-CONH-CH2 or -CH2CH2CH2-CH(NH2); and X is a pharmaceutically acceptable anion; and pharmaceutically acceptable salts of said compounds, and hydrates and solvates of the compounds of formula (I) and the salts thereof can be used in the production of medicaments for treating fungal infections and mycoses.(FR) Cette invention porte sur des dérivés azole de formule (I) dans laquelle R14 et R15 représentent chacun indépendamment hydrogène ou fluor, T représente un groupe de formule (T1) ou (T2) dans laquelle R9 représente pyrrolidinyle ou un groupe A-NH-B, A représente hydrogène ou alkyle C1-C5 à chaîne linéaire ou ramifiée, B représente alkylène C1-C4 à chaîne linéaire ou ramifiée, -CH2-CONH-CH2 ou -CH2CH2CH2-CH(NH2); et X représente un anion pharmaceutiquement acceptable. Ces dérivés azole et les sels pharmaceutiquement acceptables de ces composés ainsi que les hydrates et les solvates des composés de formule (I) et même leurs sels peuvent être utilisés dans la fabrication de médicaments destinés au traitement des infections fongiques et des mycoses.

  Azole衍生物的公式(I)，其中R14，R15分别独立表示氢或氟，T表示公式(T1)或(T2)的一个基团，其中R9表示吡咯烷基或A-NH-B-基团，A表示氢或直链或支链C1-C5烷基；B表示直链或支链C1-C4烷基，-CH2-CONH-CH2或-CH2CH2CH2-CH（NH2）；X表示药学上可接受的阴离子；公式(I)化合物的药学上可接受的盐，以及该化合物和其盐的水合物和溶剂化物可用于生产治疗真菌感染和真菌病的药物。
• US6300353B1
  申请人：——

  公开号：US6300353B1

  公开（公告）日：2001-10-09
• Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals
  作者：Jun Ohwada、Chikako Murasaki、Toshikazu Yamazaki、Shigeyasu Ichihara、Isao Umeda、Nobuo Shimma

  DOI：10.1016/s0960-894x(02)00557-7

  日期：2002.10

  Water soluble N-benzyltriazolium or N-benzylimidazolium salt type prodrugs of several highly lipophilic triazole or imidazole antifungals have been synthesized. They were designed to undergo an enzymatic activation followed by a self-cleavage to release a parent drug. The prodrugs such as 16 had enough chemical stability and water solubility for parenteral use and were rapidly and quantitatively converted to the active substance in human plasma. (C) 2002 Elsevier Science Ltd. All rights reserved.